Current trends in liposome research.

Among the several drug delivery systems, liposomes--phospholipid nanosized vesicles with a bilayered membrane structure--have drawn a lot of interest as advanced and versatile pharmaceutical carriers for both low and high molecular weight pharmaceuticals. At present, liposomal formulations span multiple areas, from clinical application of the liposomal drugs to the development of various multifunctional liposomal systems to be used in therapy and diagnostics. This chapter provides a brief overview of various liposomal products currently under development at experimental and preclinical level.

[1]  Vladimir P Torchilin,et al.  Enhanced transfection of tumor cells in vivo using “Smart” pH-sensitive TAT-modified pegylated liposomes , 2007, Journal of drug targeting.

[2]  Vladimir P Torchilin,et al.  TAT peptide-modified liposomes provide enhanced gene delivery to intracranial human brain tumor xenografts in nude mice. , 2006, Oncology research.

[3]  A. Gabizon,et al.  Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[4]  G. Storm,et al.  Specific targeting with poly(ethylene glycol)-modified liposomes: coupling of homing devices to the ends of the polymeric chains combines effective target binding with long circulation times. , 1993, Biochimica et biophysica acta.

[5]  M. Bally,et al.  Controlled destabilization of a liposomal drug delivery system enhances mitoxantrone antitumor activity , 1999, Nature Biotechnology.

[6]  Theresa M Allen,et al.  Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. , 2002, Cancer research.

[7]  Xin Yu Wang,et al.  Accelerated blood clearance of PEGylated liposomes following preceding liposome injection: effects of lipid dose and PEG surface-density and chain length of the first-dose liposomes. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[8]  F. Pastorino,et al.  Immunoliposomal fenretinide: a novel antitumoral drug for human neuroblastoma. , 2003, Cancer letters.

[9]  P. Rose,et al.  Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer. , 2005, The oncologist.

[10]  K. Edwards,et al.  Optimization and characterization of a sphingomyelin/cholesterol liposome formulation of vinorelbine with promising antitumor activity. , 2005, Journal of pharmaceutical sciences.

[11]  R. Jain,et al.  Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. , 1994, Cancer research.

[12]  Vladimir P Torchilin,et al.  Radio-frequency ablation increases intratumoral liposomal doxorubicin accumulation in a rat breast tumor model. , 2002, Radiology.

[13]  D. Lasič,et al.  Liposomes: From Physics to Applications , 1993 .

[14]  G. Adams,et al.  Monoclonal antibody therapy of cancer , 1999, Nature Biotechnology.

[15]  P. R. Veerareddy,et al.  Lipid-based formulations of amphotericin B. , 2004, Drugs of today.

[16]  D. Trombetta,et al.  Design and Characterization of Liposomes Containing Long-Chain N-AcylPEs for Brain Delivery: Penetration of Liposomes Incorporating GM1 into the Rat Brain , 2002, Pharmaceutical Research.

[17]  Samuel Zalipsky,et al.  Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates. , 2004, Advanced drug delivery reviews.

[18]  S. Thibaut,et al.  In vivo photosensitizing efficiency of a diphenylchlorin sensitizer: interest of a DMPC liposome formulation. , 2003, Pharmacological research.

[19]  J. Wilschut,et al.  Cellular Delivery of siRNA Mediated by Fusion-Active Virosomes , 2007, Journal of liposome research.

[20]  Gregory Gregoriadis,et al.  Liposome Technology, Volume I: Liposome Preparation and Related Techniques, Third Edition , 2006 .

[21]  W. Hong,et al.  Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  P. D. de Witte,et al.  Transferrin-mediated targeting of hypericin embedded in sterically stabilized PEG-liposomes. , 2002, International journal of oncology.

[23]  F. Dosio,et al.  Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential , 2006, International journal of nanomedicine.

[24]  M. Gilbert,et al.  An Open Label Trial of Sustained-release Cytarabine (DepoCyt™) for the Intrathecal Treatment of Solid Tumor Neoplastic Meningitis , 2004, Journal of Neuro-Oncology.

[25]  G. Whitman,et al.  Bioenergetic effect of liposomal coenzyme Q10 on myocardial ischemia reperfusion injury , 1999, BioFactors.

[26]  K. Ulbrich,et al.  POLY(HPMA)-COATED LIPOSOMES DEMONSTRATE PROLONGED CIRCULATION IN MICE , 2001, Journal of liposome research.

[27]  Carl O. Pabo,et al.  Cellular uptake of the tat protein from human immunodeficiency virus , 1988, Cell.

[28]  H. Yanagie,et al.  Liposomes Bearing Polyethyleneglycol-Coupled Transferrin with Intracellular Targeting Property to the Solid Tumors In Vivo , 2001, Pharmaceutical Research.

[29]  R. Marchant,et al.  RGD-modified liposomes targeted to activated platelets as a potential vascular drug delivery system , 2004, Thrombosis and Haemostasis.

[30]  W. Oyen,et al.  Factors affecting the accelerated blood clearance of polyethylene glycol-liposomes upon repeated injection. , 2001, The Journal of pharmacology and experimental therapeutics.

[31]  P. Low,et al.  Folate targeting of haptens to cancer cell surfaces mediates immunotherapy of syngeneic murine tumors , 2002, Cancer Immunology, Immunotherapy.

[32]  V. Torchilin.  Surface-modified liposomes in gamma- and MR-imaging , 1997 .

[33]  G. Cevc,et al.  New, highly efficient formulation of diclofenac for the topical, transdermal administration in ultradeformable drug carriers, Transfersomes. , 2001, Biochimica et biophysica acta.

[34]  M. Brandl,et al.  Biodistribution and computed tomography blood-pool imaging properties of polyethylene glycol-coated iopromide-carrying liposomes. , 1997, Investigative radiology.

[35]  N. Van Rooijen,et al.  Effect of liposome size on the circulation time and intraorgan distribution of amphipathic poly(ethylene glycol)-containing liposomes. , 1994, Biochimica et biophysica acta.

[36]  D. Papahadjopoulos,et al.  Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. , 1999, Pharmacological reviews.

[37]  J. Wilschut,et al.  Influenza virosomes in vaccine development. , 2003, Methods in enzymology.

[38]  J. Huwyler,et al.  Brain drug delivery of small molecules using immunoliposomes. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Kazuo Maruyama,et al.  Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes , 1990, FEBS letters.

[40]  G. Hortobagyi,et al.  Phase II study of liposomal annamycin in the treatment of doxorubicin-resistant breast cancer , 2002, Cancer Chemotherapy and Pharmacology.

[41]  D. D. De Vos,et al.  Targeting of the photocytotoxic compound AlPcS4 to hela cells by transferrin conjugated peg‐liposomes , 2002, International journal of cancer.

[42]  V. Torchilin.  Liposomes as targetable drug carriers. , 1985, Critical reviews in therapeutic drug carrier systems.

[43]  M. Hussein,et al.  Role of liposomal anthracyclines in the treatment of multiple myeloma. , 2004, Seminars in oncology.

[44]  N. Chiaramoni,et al.  Stability of Liposomal Formulations in Physiological Conditions for Oral Drug Delivery , 2004, Drug delivery.

[45]  M. Sasamata,et al.  Real-time blood-pool images of contrast enhanced ultrasound with Definity in the detection of tumour nodules in the liver. , 2005, The British journal of radiology.

[46]  B. Ruf,et al.  Open, Randomized Study to Compare the Immunogenicity and Reactogenicity of an Influenza Split Vaccine with an MF59-Adjuvanted Subunit Vaccine and a Virosome-Based Subunit Vaccine in Elderly , 2004, Infection.

[47]  T. Porter,et al.  Detection of Coronary Artery Disease with a Continuous Infusion of Definity Ultrasound Contrast during Adenosine Stress Real Time Perfusion Echocardiography , 2007, Echocardiography.

[48]  U. Nielsen,et al.  Tumor targeting using anti-her2 immunoliposomes. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[49]  Y. Tseng,et al.  Translocation of liposomes into cancer cells by cell-penetrating peptides penetratin and tat: a kinetic and efficacy study. , 2002, Molecular pharmacology.

[50]  Vladimir P Torchilin,et al.  Tumor-targeted liposomes: doxorubicin-loaded long-circulating liposomes modified with anti-cancer antibody. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[51]  T. Andresen,et al.  Activation of the Human Complement System by Cholesterol-Rich and PEGylated Liposomes—Modulation of Cholesterol-Rich Liposome-Mediated Complement Activation by Elevated Serum LDL and HDL Levels , 2006, Journal of liposome research.

[52]  J. Gottdiener,et al.  Efficacy and safety of the novel ultrasound contrast agent perflutren (definity) in patients with suboptimal baseline left ventricular echocardiographic images. , 2000, The American journal of cardiology.

[53]  Adenosine Triphosphate Liposomes: Encapsulation and Distribution Studies , 1990, Pharmaceutical Research.

[54]  L. Recht,et al.  A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[55]  F. Khuri,et al.  A phase II study of STEALTH cisplatin (SPI-77) in patients with advanced non-small cell lung cancer. , 2001, Lung cancer.

[56]  D. Alberts,et al.  Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials. , 2004, Seminars in oncology.

[57]  U. Matulonis,et al.  A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer. , 2004, Gynecologic oncology.

[58]  Vladimir P Torchilin,et al.  Tumor-specific antibody-mediated targeted delivery of Doxil reduces the manifestation of auricular erythema side effect in mice. , 2008, International journal of pharmaceutics.

[59]  N. Oku,et al.  Antiangiogenic photodynamic therapy (PDT) using Visudyne causes effective suppression of tumor growth. , 2004, Cancer letters.

[60]  M. Shoji,et al.  Targeting of post-ischemic cerebral endothelium in rat by liposomes bearing polyethylene glycol-coupled transferrin , 2003, Neurological research.

[61]  P. Low,et al.  Characterization of a novel pH-sensitive peptide that enhances drug release from folate-targeted liposomes at endosomal pHs. , 2002, Biochimica et biophysica acta.

[62]  P. Ježek,et al.  Experimental photodynamic therapy with MESO‐tetrakisphenylporphyrin (TPP) in liposomes leads to disintegration of human amelanotic melanoma implanted to nude mice , 2003, International journal of cancer.

[63]  K. Maruyama,et al.  Intracellular targeting therapy of cisplatin‐encapsulated transferrin‐polyethylene glycol liposome on peritoneal dissemination of gastric cancer , 2002, International journal of cancer.

[64]  John W. Park,et al.  Preclinical Manufacture of Anti‐HER2 Liposome‐Inserting, scFv‐PEG‐Lipid Conjugate. 2. Conjugate Micelle Identity, Purity, Stability, and Potency Analysis , 2008, Biotechnology progress.

[65]  T. Murakami,et al.  Targeted systemic chemotherapy using magnetic liposomes with incorporated adriamycin for osteosarcoma in hamsters. , 2001, International journal of oncology.

[66]  Peter Babinec,et al.  Site-Specific in vivo Targeting of Magnetoliposomes Using Externally Applied Magnetic Field , 2000, Zeitschrift fur Naturforschung. C, Journal of biosciences.

[67]  V. Awasthi,et al.  Kinetics of liposome-encapsulated hemoglobin after 25% hypovolemic exchange transfusion. , 2004, International journal of pharmaceutics.

[68]  G. Gazelle,et al.  Percutaneous tumor ablation: increased necrosis with combined radio-frequency ablation and intravenous liposomal doxorubicin in a rat breast tumor model. , 2002, Radiology.

[69]  V. Awasthi,et al.  Polyethylene glycol-modified liposome-encapsulated hemoglobin: a long circulating red cell substitute. , 1999, The Journal of pharmacology and experimental therapeutics.

[70]  G. Brix,et al.  Paclitaxel encapsulated in cationic lipid complexes (MBT-0206) impairs functional tumor vascular properties as detected by dynamic contrast enhanced magnetic resonance imaging , 2006, Cancer biology & therapy.

[71]  Yuzuru Ikehara,et al.  Development of a novel oligomannose-coated liposome-based anticancer drug-delivery system for intraperitoneal cancer. , 2007, Current opinion in molecular therapeutics.

[72]  Babich,et al.  Long-circulating gadolinium-loaded liposomes: potential use for magnetic resonance imaging of the blood pool. , 2000, Colloids and surfaces. B, Biointerfaces.

[73]  Samuel A Wickline,et al.  Targeted contrast agents for magnetic resonance imaging and ultrasound. , 2005, Current opinion in biotechnology.

[74]  L. Huang,et al.  pH-sensitive liposomes: acid-induced liposome fusion. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[75]  S. Magdassi,et al.  Liposome transduction into cells enhanced by haptotactic peptides (Haptides) homologous to fibrinogen C-termini. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[76]  J. Benoit,et al.  Serum-stable and long-circulating, PEGylated, pH-sensitive liposomes. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[77]  W. Hennink,et al.  A novel family of L-amino acid-based biodegradable polymer-lipid conjugates for the development of long-circulating liposomes with effective drug-targeting capacity. , 2003, Bioconjugate chemistry.

[78]  A. Gabizon.  Pegylated Liposomal Doxorubicin: Metamorphosis of an Old Drug into a New Form of Chemotherapy , 2001, Cancer investigation.

[79]  A. Bedikian,et al.  Pharmacokinetics and Urinary Excretion of Vincristine Sulfate Liposomes Injection in Metastatic Melanoma Patients , 2006, Journal of clinical pharmacology.

[80]  V. Torchilin,et al.  TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[81]  J. M. Harris,et al.  Pegylation: a novel process for modifying pharmacokinetics. , 2001, Clinical pharmacokinetics.

[82]  C. Benz,et al.  Liposome targeting to tumors using vitamin and growth factor receptors. , 2000, Vitamins and hormones.

[83]  Thomas Rades,et al.  Lipid based particulate formulations for the delivery of antigen , 2005, Immunology and cell biology.

[84]  P. Jerabek,et al.  Cerebral oxygen delivery by liposome-encapsulated hemoglobin: a positron-emission tomographic evaluation in a rat model of hemorrhagic shock. , 2007, Journal of applied physiology.

[85]  R. Herrmann,et al.  EGFR-targeted immunoliposomes derived from the monoclonal antibody EMD72000 mediate specific and efficient drug delivery to a variety of colorectal cancer cells , 2006, Journal of drug targeting.

[86]  D. Weiner,et al.  First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. , 1998, The Journal of infectious diseases.

[87]  V. Torchilin,et al.  p-Nitrophenylcarbonyl-PEG-PE-liposomes: fast and simple attachment of specific ligands, including monoclonal antibodies, to distal ends of PEG chains via p-nitrophenylcarbonyl groups. , 2001, Biochimica et biophysica acta.

[88]  Y. Tsutsumi,et al.  Bioconjugation of laminin peptide YIGSR with poly(styrene co-maleic acid) increases its antimetastatic effect on lung metastasis of B16-BL6 melanoma cells. , 1999, Biochemical and biophysical research communications.

[89]  M. Kim,et al.  Enhanced transfollicular delivery of adriamycin with a liposome and iontophoresis , 2004, Experimental dermatology.

[90]  D Needham,et al.  Repulsive interactions and mechanical stability of polymer-grafted lipid membranes. , 1992, Biochimica et biophysica acta.

[91]  T. Allen,et al.  Pharmacokinetics of stealth versus conventional liposomes: effect of dose. , 1991, Biochimica et biophysica acta.

[92]  Werner Tjarks,et al.  A novel pH-sensitive liposome formulation containing oleyl alcohol. , 2002, Biochimica et biophysica acta.

[93]  Sérgio Simões,et al.  On the formulation of pH-sensitive liposomes with long circulation times. , 2004, Advanced drug delivery reviews.

[94]  V. Torchilin,et al.  Enhanced tumor visualization by gamma-scintigraphy with 111In-labeled polychelating-polymer-containing immunoliposomes. , 2006, Molecular pharmaceutics.

[95]  G. Betageri,et al.  Transdermal iontophoretic delivery of enkephalin formulated in liposomes. , 1996, Journal of pharmaceutical sciences.

[96]  V. Torchilin,et al.  Enhanced cytotoxicity of monoclonal anticancer antibody 2C5-modified doxorubicin-loaded PEGylated liposomes against various tumor cell lines. , 2007, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[97]  H. Karanth,et al.  pH‐Sensitive liposomes‐principle and application in cancer therapy , 2007, The Journal of pharmacy and pharmacology.

[98]  A. Asokan,et al.  Cytosolic delivery of macromolecules. II. Mechanistic studies with pH-sensitive morpholine lipids. , 2003, Biochimica et biophysica acta.

[99]  I. Rubinstein,et al.  VIP grafted sterically stabilized liposomes for targeted imaging of breast cancer: in vivo studies. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[100]  D. Carbonaro,et al.  Preclinical safety, pharmacokinetics and antitumor efficacy profile of liposome-entrapped SN-38 formulation. , 2005, Anticancer research.

[101]  V. Torchilin,et al.  Which polymers can make nanoparticulate drug carriers long-circulating? , 1995 .

[102]  M. Woodle,et al.  Long Circulating Liposomes: Old Drugs, New Therapeutics , 1998, Biotechnology Intelligence Unit.

[103]  Robert J. Lee,et al.  Antitumor Activity of Folate Receptor-Targeted Liposomal Doxorubicin in a KB Oral Carcinoma Murine Xenograft Model , 2003, Pharmaceutical Research.

[104]  D. Papahadjopoulos,et al.  Medical applications of liposomes , 1998 .

[105]  M. Woodle,et al.  Controlling liposome blood clearance by surface-grafted polymers. , 1998, Advanced drug delivery reviews.

[106]  Robert J. Lee,et al.  Folate receptor targeted delivery of liposomal daunorubicin into tumor cells. , 2002, Anticancer research.

[107]  R. Perez-soler,et al.  Preclinical toxicity of liposome-incorporated annamycin: selective bone marrow toxicity with lack of cardiotoxicity. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[108]  G Blume,et al.  Molecular mechanism of the lipid vesicle longevity in vivo. , 1993, Biochimica et biophysica acta.

[109]  Vladimir P Torchilin,et al.  Cell transfection in vitro and in vivo with nontoxic TAT peptide-liposome–DNA complexes , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[110]  S. Phuphanich,et al.  A pharmacokinetic study of intra-CSF administered encapsulated cytarabine (DepoCyt®) for the treatment of neoplastic meningitis in patients with leukemia, lymphoma, or solid tumors as part of a phase III study , 2006, Journal of Neuro-Oncology.

[111]  S. Yamashita,et al.  Application of polyethyleneglycol (PEG)-modified liposomes for oral vaccine: effect of lipid dose on systemic and mucosal immunity. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[112]  H. Maeda,et al.  Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[113]  P. Cheng,et al.  Transferrin-facilitated lipofection gene delivery strategy: characterization of the transfection complexes and intracellular trafficking. , 2002, Human gene therapy.

[114]  R. Schiffelers,et al.  Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[115]  Theresa M Allen,et al.  Advantages of liposomal delivery systems for anthracyclines. , 2004, Seminars in oncology.

[116]  Magnetic resonance lymphography of profundus lymph nodes with liposomal gadolinium-diethylenetriamine pentaacetic acid. , 2000, Biological & pharmaceutical bulletin.

[117]  T. Minko,et al.  New generation of liposomal drugs for cancer. , 2006, Anti-cancer agents in medicinal chemistry.

[118]  T. Suhara,et al.  Factors governing the in vivo tissue uptake of transferrin-coupled polyethylene glycol liposomes in vivo. , 2004, International journal of pharmaceutics.

[119]  C. Mamot,et al.  Liposome-based approaches to overcome anticancer drug resistance. , 2003, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[120]  G. Cevc.  Lipid vesicles and other colloids as drug carriers on the skin. , 2004, Advanced drug delivery reviews.

[121]  T. Allen,et al.  Subcutaneous administration of liposomes: a comparison with the intravenous and intraperitoneal routes of injection. , 1993, Biochimica et biophysica acta.

[122]  V. Georgoulias,et al.  Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[123]  M. Daidone,et al.  Effects of liposome‐entrapped annamycin in human breast cancer cells: Interference with cell cycle progression and induction of apoptosis , 2001, Journal of cellular biochemistry.

[124]  A. Maitra,et al.  Targeted cytosolic delivery of hydrogel nanoparticles into HepG2 cells through engineered Sendai viral envelopes , 2002, FEBS letters.

[125]  Jianwei Zhu,et al.  Preclinical Manufacture of an Anti‐HER2 scFv‐PEG‐DSPE, Liposome‐Inserting Conjugate. 1. Gram‐Scale Production and Purification , 2008, Biotechnology progress.

[126]  S. Mantripragada.  A lipid based depot (DepoFoam technology) for sustained release drug delivery. , 2002, Progress in lipid research.

[127]  D. Lacombe,et al.  Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck. An EORTC New Drug Development Group study. , 2004, European journal of cancer.

[128]  R. Perez-soler,et al.  Antitumor activity of free and liposome-entrapped annamycin, a lipophilic anthracycline antibiotic with non-cross-resistance properties. , 1994, Cancer research.

[129]  W. Zamboni.  Liposomal, Nanoparticle, and Conjugated Formulations of Anticancer Agents , 2005, Clinical Cancer Research.

[130]  Tatsuo Tanaka,et al.  Liposomal photofrin enhances therapeutic efficacy of photodynamic therapy against the human gastric cancer. , 2003, Toxicology letters.

[131]  Steven F Dowdy,et al.  Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis , 2004, Nature Medicine.

[132]  B. L. Wylie,et al.  Arginine-rich molecular transporters for drug delivery: role of backbone spacing in cellular uptake. , 2002, Journal of medicinal chemistry.

[133]  T. Boulikas,et al.  Systemic Lipoplatin infusion results in preferential tumor uptake in human studies. , 2005, Anticancer research.

[134]  V. Torchilin,et al.  Design, synthesis, and characterization of pH-sensitive PEG-PE conjugates for stimuli-sensitive pharmaceutical nanocarriers: the effect of substitutes at the hydrazone linkage on the ph stability of PEG-PE conjugates. , 2007, Bioconjugate chemistry.

[135]  Y. Perrie,et al.  Particulate delivery systems for vaccines. , 2005, Critical reviews in therapeutic drug carrier systems.

[136]  S M Moghimi,et al.  Chemical camouflage of nanospheres with a poorly reactive surface: towards development of stealth and target-specific nanocarriers. , 2002, Biochimica et biophysica acta.

[137]  Y. Barenholz,et al.  Gelation of liposome interior A novel method for drug encapsulation , 1992, FEBS letters.

[138]  S. Wagner,et al.  Preparation and Evaluation of Lyophilized Iopromide‐Carrying Liposomes for Liver Tumor Detection , 1993, Investigative radiology.

[139]  H. Junginger,et al.  Transdermal Delivery of Pergolide from Surfactant-Based Elastic and Rigid Vesicles: Characterization and in Vitro Transport Studies , 2002, Pharmaceutical Research.

[140]  P. D. de Witte,et al.  Liposomes for photodynamic therapy. , 2004, Advanced drug delivery reviews.

[141]  Kostas Kostarelos,et al.  Construction of nanoscale multicompartment liposomes for combinatory drug delivery. , 2007, International journal of pharmaceutics.

[142]  Leaf Huang,et al.  Non-viral vector as vaccine carrier. , 2005, Advances in genetics.

[143]  P. Low,et al.  Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. , 1994, The Journal of biological chemistry.

[144]  A M Tsatsakis,et al.  Amphiphilic poly-N-vinylpyrrolidones: synthesis, properties and liposome surface modification. , 2001, Biomaterials.

[145]  D. Osoba,et al.  Use of liposomal anthracyclines in Kaposi's sarcoma. , 2004, Seminars in oncology.

[146]  V. Torchilin,et al.  Organelle-targeted nanocarriers: specific delivery of liposomal ceramide to mitochondria enhances its cytotoxicity in vitro and in vivo. , 2008, Nano letters.

[147]  J H Senior,et al.  Fate and behavior of liposomes in vivo: a review of controlling factors. , 1987, Critical reviews in therapeutic drug carrier systems.

[148]  U. Bogdahn,et al.  Pegylated liposomal doxorubicin‐efficacy in patients with recurrent high‐grade glioma , 2004, Cancer.

[149]  Philip S Low,et al.  Folate-mediated delivery of macromolecular anticancer therapeutic agents. , 2002, Advanced drug delivery reviews.

[150]  G. Hardee,et al.  Folate-liposome-mediated antisense oligodeoxynucleotide targeting to cancer cells: evaluation in vitro and in vivo. , 2003, Bioconjugate chemistry.

[151]  M. Dewhirst,et al.  In vivo monitoring of tissue pharmacokinetics of liposome/drug using MRI: Illustration of targeted delivery , 2004, Magnetic resonance in medicine.

[152]  E. Chang,et al.  Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes. , 2002, Molecular cancer therapeutics.

[153]  S. Kawakami,et al.  Optimization of tumor-selective targeting by basic fibroblast growth factor-binding peptide grafted PEGylated liposomes. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[154]  J. Klaveness,et al.  Biodistribution of pH-responsive liposomes for MRI and a novel approach to improve the pH-responsiveness. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[155]  J. Schellens,et al.  Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma , 2004, Cancer Chemotherapy and Pharmacology.

[156]  D F P Larkin,et al.  Antibody targeted gene transfer to endothelium , 2003, The journal of gene medicine.

[157]  Novel method of greatly enhanced delivery of liposomes to lymph nodes. , 2000, The Journal of pharmacology and experimental therapeutics.

[158]  U. Nielsen,et al.  Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. , 2006, Cancer research.

[159]  J. Chaumeil,et al.  Hepatic Preservation, Liposomally Entrapped Adenosine Triphosphate and Nitric Oxide Production: a Study of Energy State and Protein Metabolism in the Cold-Stored Rat Liver , 2002, Scandinavian journal of gastroenterology.

[160]  E. Winer,et al.  The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer. , 2004, Seminars in oncology.

[161]  T. Boulikas,et al.  Pharmacokinetics and adverse reactions of a new liposomal cisplatin (Lipoplatin): phase I study. , 2005, Oncology reports.

[162]  R. Bankert,et al.  THE NEXT GENERATION OF LIPOSOME DELIVERY SYSTEMS: RECENT EXPERIENCE WITH TUMOR-TARGETED, STERICALLY-STABILIZED IMMUNOLIPOSOMES AND ACTIVE-LOADING GRADIENTS , 2002, Journal of liposome research.

[163]  Toshinori Ito,et al.  Novel chondroitin sulfate-binding cationic liposomes loaded with cisplatin efficiently suppress the local growth and liver metastasis of tumor cells in vivo. , 2002, Cancer research.

[164]  Bhawna Gupta,et al.  Monoclonal antibody 2C5-modified doxorubicin-loaded liposomes with significantly enhanced therapeutic activity against intracranial human brain U-87 MG tumor xenografts in nude mice , 2007, Cancer Immunology, Immunotherapy.

[165]  Bruce Miller,et al.  Preparation, Characterization, and Stability of Liposome-Based Formulations of Mitoxantrone , 2005, Drug development and industrial pharmacy.

[166]  Robert J. Lee,et al.  Folate receptor-targeted liposomes as possible delivery vehicles for boron neutron capture therapy. , 2003, Anticancer research.

[167]  J. Viret,et al.  Virosomal adjuvanted antigen delivery systems , 2003, Expert review of vaccines.

[168]  Yechezkel Barenholz,et al.  Pharmacokinetics of Pegylated Liposomal Doxorubicin , 2003, Clinical pharmacokinetics.

[169]  P. Low,et al.  Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[170]  V. Torchilin.  Liposomes as delivery agents for medical imaging. , 1996, Molecular medicine today.

[171]  P. Chien,et al.  Enhanced therapeutic efficacy of a novel liposome-based formulation of SN-38 against human tumor models in SCID mice , 2004, Anti-cancer drugs.

[172]  C K Kim,et al.  Lymphatic delivery and pharmacokinetics of methotrexate after intramuscular injection of differently charged liposome-entrapped methotrexate to rats. , 1995, Journal of microencapsulation.

[173]  C. Herzog,et al.  Rapid Antibody Response after Vaccination with a Virosomal Hepatitis A Vaccine , 2004, Infection.

[174]  Vladimir P. Torchilin,et al.  ATP-Loaded Liposomes Effectively Protect the Myocardium in Rabbits with an Acute Experimental Myocardial Infarction , 2005, Pharmaceutical Research.

[175]  V. Torchilin,et al.  Encapsulation of ATP into liposomes by different methods: optimization of the procedure , 2004, Journal of microencapsulation.

[176]  V. Torchilin,et al.  Gadolinium-Loaded Polychelating Polymer-Containing Cancer Cell-Specific Immunoliposomes , 2006, Journal of liposome research.

[177]  P. Couvreur,et al.  Intracarotidal administration of liposomally-entrapped ATP: improved efficiency against experimental brain ischemia. , 1988, Pharmacological research communications.

[178]  V. Torchilin,et al.  Targeted accumulation of polyethylene glycol‐coated immunoliposomes in infarcted rabbit myocardium , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[179]  J. Zhang,et al.  Development and characterization of a novel Cremophor EL free liposome-based paclitaxel (LEP-ETU) formulation. , 2005, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[180]  V. Torchilin,et al.  Protective Effect of Coenzyme Q10-loaded Liposomes on the Myocardium in Rabbits with an Acute Experimental Myocardial Infarction , 2007, Pharmaceutical Research.

[181]  J. V. Moran,et al.  Initial sequencing and analysis of the human genome. , 2001, Nature.

[182]  C. Mamot,et al.  Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. , 2005, Cancer research.

[183]  J. Wilschut,et al.  Delivery of Protein Antigens to the Immune System by Fusion-Active Virosomes: A Comparison with Liposomes and ISCOMs , 2002, Bioscience reports.

[184]  A. Bao,et al.  A novel liposome radiolabeling method using 99mTc-"SNS/S" complexes: in vitro and in vivo evaluation. , 2003, Journal of pharmaceutical sciences.

[185]  V. Usonis,et al.  Antibody titres after primary and booster vaccination of infants and young children with a virosomal hepatitis A vaccine (Epaxal). , 2003, Vaccine.

[186]  V. Torchilin.  Recent advances with liposomes as pharmaceutical carriers , 2005, Nature Reviews Drug Discovery.

[187]  W. Jiskoot,et al.  Functional Characterization of an Endosome-disruptive Peptide and Its Application in Cytosolic Delivery of Immunoliposome-entrapped Proteins* , 2002, The Journal of Biological Chemistry.

[188]  Timothy B. Stockwell,et al.  The Sequence of the Human Genome , 2001, Science.

[189]  M. Hashida,et al.  Control of pharmaceutical properties of soybean trypsin inhibitor by conjugation with dextran. II: Biopharmaceutical and pharmacological properties. , 1989, Journal of pharmaceutical sciences.

[190]  Sanjay K. Jain,et al.  Design and development of folate appended liposomes for enhanced delivery of 5-FU to tumor cells , 2007, Journal of drug targeting.

[191]  V. Torchilin.  Polymeric contrast agents for medical imaging. , 2000, Current pharmaceutical biotechnology.

[192]  J. Kamps,et al.  Uptake of Long-Circulating Immunoliposomes, Directed Against Colon Adenocarcinoma Cells, by Liver Metastases of Colon Cancer , 2000, Journal of drug targeting.

[193]  M. Nango,et al.  Intracellular target for photosensitization in cancer antiangiogenic photodynamic therapy mediated by polycation liposome. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[194]  Takashi Sugita,et al.  Evaluation of systemic chemotherapy with magnetic liposomal doxorubicin and a dipole external electromagnet , 2004, International journal of cancer.

[195]  Y. Quinn,et al.  New detachable poly(ethylene glycol) conjugates: cysteine-cleavable lipopolymers regenerating natural phospholipid, diacyl phosphatidylethanolamine. , 1999, Bioconjugate chemistry.

[196]  C. Herzog,et al.  Virosome influenza vaccine in children. , 2002, Vaccine.

[197]  V. Torchilin,et al.  Liposomes : a practical approach , 2003 .

[198]  D. Peer,et al.  Loading mitomycin C inside long circulating hyaluronan targeted nano‐liposomes increases its antitumor activity in three mice tumor models , 2004, International journal of cancer.

[199]  P. Correale,et al.  Efficient delivery of DNA to dendritic cells mediated by influenza virosomes. , 2004, Vaccine.

[200]  D. Alberts,et al.  Role of pegylated liposomal doxorubicin in ovarian cancer. , 2005, Gynecologic oncology.

[201]  S. Shuto,et al.  Anti‐neovascular therapy by liposomal DPP‐CNDAC targeted to angiogenic vessels , 2002, FEBS letters.

[202]  J. Wilschut,et al.  Virosome-mediated delivery of protein antigens to dendritic cells. , 2002, Vaccine.

[203]  Y. Kawashima,et al.  Evaluation of circulation profiles of liposomes coated with hydrophilic polymers having different molecular weights in rats. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[204]  S. Lesieur,et al.  Sterically stabilized superparamagnetic liposomes for MR imaging and cancer therapy: pharmacokinetics and biodistribution. , 2007, International journal of pharmaceutics.

[205]  L. Xie,et al.  Oral colon-specific drug delivery for bee venom peptide: development of a coated calcium alginate gel beads-entrapped liposome. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[206]  M. Bally,et al.  Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models. , 2000, Cancer research.

[207]  R. Vile,et al.  Phase I-II study of pegylated liposomal cisplatin (SPI-077) in patients with inoperable head and neck cancer. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[208]  Kazuo Maruyama,et al.  Transferrin-modified liposomes equipped with a pH-sensitive fusogenic peptide: an artificial viral-like delivery system. , 2004, Biochemistry.

[209]  R. Bellamkonda,et al.  Targeted drug delivery to C6 glioma by transferrin-coupled liposomes. , 2000, Journal of biomedical materials research.

[210]  V. Torchilin,et al.  ATP-loaded immunoliposomes specific for cardiac myosin provide improved protection of the mechanical functions of myocardium from global ischemia in an isolated rat heart model , 2006, Journal of drug targeting.